2
Executive Summary
Biosimilars Finally Prepared to Make Their Mark
The authors of this report wish to acknowledge the contribution made by Selvakumar Nallasamy and Brajesh Nirala, employees of CRISIL Global Research and Analytics, a business division
of CRISIL Limited. CRISIL Limited is a third-party provider of offshore research services to Credit Suisse.Greater Proportion of Branded Prescription Drug Sales Coming from
Biologics and Complex Molecules
Biosimilars Market Opportunity
Source: Credit Suisse PharmaValues Database and Credit Suisse Analysis
Global Branded Prescription Drug Sales Estimate by Molecule Type
(Sales in $ Bn)
20102011201220132014201520162017201820192020202120222023
Small MoleculeBiologics/Complex moleculesVaccinesOthers
*Note: Throughout the analyses in this note, complex small molecule drugs (ex: Copaxone, Invega Sustenna) are classified under biological category
An estimated ~$115Bn of $293Bn (based on 2022 sales) in annual global biological sales is expected to
no longer have patent protection by 2023, leaving door wide open for biosimilar competitionNow in the Middle Innings of a Robust Period of Patent Expiries for
Branded Biologic Products
Biosimilars Market Opportunity
Source: Credit Suisse PharmaValues Database and Credit Suisse Analysis
Sales During the Year Before Patent Expiry of Biologics Whose Patent Expire by 2023
(Year of Patent Expiry in X axis; Prior Year Sales in $ Bn in Y axis)
20102011201220132014201520162017201820192020202120222023
Ex-US$0.8$0.7$5.2$2.0$11.7$13.3$1.3$4.9$12.0$4.8$2.4$6.4$5.7$2.4
US$0.7$0.3$3.5$2.2$2.3$12.7$1.3$10.9$7.3$12.5$3.5$3.5$23.2$1.0。。。